7月16日，莫德纳盘中下跌5.52%，报64.51美元/股，成交额1.38亿美元。
消息面上，生物制药公司Arbutus Biopharma宣布已收到莫德纳专利侵权和解协议项下约1.78亿美元的首笔非或有付款分成。这笔大额支出对莫德纳的现金流及短期盈利能力构成压力，尤其在公司下次财报（预期EPS为-1.99美元）即将于7月31日发布之际，投资者对其财务状况的担忧进一步加剧。同日，莫德纳宣布其肿瘤靶向癌症抗原疗法一期临床试验首例患者完成给药，但积极的管线进展未能抵消专利和解付款带来的负面情绪。当前生物科技行业中，艾伯维涨2.67%、安进涨2.81%、吉利德科学涨0.96%，莫德纳明显跑输同业。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.